Literature DB >> 23100244

Behavioral paradigms to evaluate PPAR modulation in animal models of brain injury.

Dana Greene-Schloesser1, Caroline I Schnegg, Mike E Robbins.   

Abstract

The use of behavioral testing has become an invaluable tool for assessing the efficacy of therapeutics for a variety of disorders of the central nervous system. This chapter will describe in detail several behavioral paradigms to evaluate the efficacy of PPAR agonists to modulate cognitive impairments in rodent models. When used together as a battery these procedures allow for a global assessment of cognition. These tests are explained in detail below, and include: (1) Novel Object Recognition (NOR), (2) Morris Water Maze (MWM), (3) Delay Match to Place (DMP), and (4) Cue Strategy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23100244      PMCID: PMC3795415          DOI: 10.1007/978-1-62703-155-4_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  27 in total

Review 1.  Predicting drug efficacy for cognitive deficits in schizophrenia.

Authors:  Jim J Hagan; Declan N C Jones
Journal:  Schizophr Bull       Date:  2005-09-21       Impact factor: 9.306

2.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

Authors:  G Stennis Watson; Brenna A Cholerton; Mark A Reger; Laura D Baker; Stephen R Plymate; Sanjay Asthana; Mark A Fishel; J Jacob Kulstad; Pattie S Green; David G Cook; Steven E Kahn; Michelle L Keeling; Suzanne Craft
Journal:  Am J Geriatr Psychiatry       Date:  2005-11       Impact factor: 4.105

3.  ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro.

Authors:  Justyna Drukala; Katarzyna Urbanska; Anna Wilk; Maja Grabacka; Ewa Wybieralska; Luis Del Valle; Zbigniew Madeja; Krzysztof Reiss
Journal:  Mol Cancer       Date:  2010-06-22       Impact factor: 27.401

4.  Monitoring spatial learning and memory in Alzheimer's disease mouse models using the Morris Water Maze.

Authors:  Kimberly Scearce-Levie
Journal:  Methods Mol Biol       Date:  2011

5.  Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.

Authors:  Torben Glatz; Ivonne Stöck; Miriam Nguyen-Ngoc; Peter Gohlke; Thomas Herdegen; Juraj Culman; Yi Zhao
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

6.  PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.

Authors:  Wen Huang; Sung Yong Eum; Ibolya E András; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

7.  Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes.

Authors:  Servio H Ramirez; David Heilman; Brenda Morsey; Raghava Potula; James Haorah; Yuri Persidsky
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

8.  Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.

Authors:  Pramod Kumar; Ravinder K Kaundal; Sandeep More; Shyam S Sharma
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

9.  Developments of a water-maze procedure for studying spatial learning in the rat.

Authors:  R Morris
Journal:  J Neurosci Methods       Date:  1984-05       Impact factor: 2.390

10.  PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

Authors:  Nicoletta Schintu; Lucia Frau; Marcello Ibba; Pierluigi Caboni; Arianna Garau; Ezio Carboni; Anna R Carta
Journal:  Eur J Neurosci       Date:  2009-02-24       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.